Antibody 3BNC117 suppresses HIV for a relatively long time


View:489 Time:2016-07-27


After years of efforts, scientists have developed antiretroviral therapy (ART) to fight HIV infection. ART is effective for improving immunity and reducing life-threatening complications in HIV infected people. For this reason, ART becomes a standard treatment for HIV. However, there is still no cure for HIV infection. Currently, patients have to take ART drugs every day, which may lead to adverse effects over time.

According to a new study reported in Nature, Rockefeller researchers found that a new HIV therapy using antibodies could have long-acting effects and would reduce the dose. The antibody termed 3BNC117 efficiently retarded the viral rebound in HIV-infected individuals who temporarily stopped taking ART drugs. Marina Caskey noted that the findings were significant because the antibody delayed the virus rebound for a relatively long time.

A few years ago, Johannes Scheid, author of this new study, isolated cells from an HIV-infected person whose immune system fought the virus well, and then developed the 3BNC117 antibody from these cells. HIV infects vital cells in the human immune system, such as CD4+ T cells. 3BNC117 prevents some HIV strains from hijacking CD4+ T cells.

ART medicines work by suppressing the replication of HIV. Unfortunately, HIV can remain dormant in CD4 cells and is able to come roaring back in everyone who stops taking the drugs.

The new study included 13 HIV-infected people who had been treated successfully with ART drugs. The researchers aimed to identify whether the 3BNC117 antibody alone can suppress HIV. They treated the patients with 3BNC117 alone. The results showed that the antibody delayed the virus rebound for nearly 10 weeks, longer than 3 weeks in the control group.
 
About news

Newsletters

Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

Copyright © 2007-2018 www.cusabio.com CUSABIO TECHNOLOGY LLC All Rights Reserved.

Wait!

Join the 25,000 subscribers to get research hotpots, technical tips, latest information on events, sales and offers.

Sign up now!

We don't deal in spam.